World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
37242
World Ranking
5832
National Ranking
3131

Mark Krailo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark Krailo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 483 publications — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark Krailo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark Krailo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark Krailo is affiliated with the University of Southern California in the United States and has a substantial record of research publications within medicine and related fields. Their work spans several subfields, including pulmonary and respiratory medicine, surgery, neurology, cancer research, and molecular biology.

They have contributed extensively to topics such as sarcoma diagnosis and treatment, neuroblastoma research and treatments, testicular diseases and treatments, cancer genomics and diagnostics, lymphoma diagnosis and treatment, glioma diagnosis and treatment, and hepatocellular carcinoma treatment and prognosis.

Mark Krailo's recent publications include:

  • Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children's Oncology Group Trial ACNS0333, 2020, Journal of Clinical Oncology
  • Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol, 2021, Journal of Clinical Oncology
  • Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group, 2023, Journal of Clinical Oncology
  • Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial, 2021, Pediatric Blood & Cancer
  • The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database, 2020, Pediatric Blood & Cancer

Frequent co-authors collaborating with Mark Krailo include:

  • Katherine A. Janeway
  • Allen Buxton
  • Steven G. DuBois
  • Damon R. Reed
  • Richard Görlick

Their research has been published predominantly in the following venues:

  • Journal of Clinical Oncology
  • Pediatric Blood & Cancer
  • European Journal of Cancer
  • Neuro-Oncology
  • Journal of Pediatric Surgery

Mark Krailo's scholarly contributions cover a broad range of medical sciences, bridging clinical treatment approaches with molecular and genetic insights, especially within oncology and pediatric diseases. Their work reflects involvement in multi-institutional clinical trials and collaborations within the Children's Oncology Group and other research consortia.

Best Publications

  • Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

    Holcombe E Grier;Mark D Krailo;Nancy J Tarbell;Michael P Link

  • ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer

    M C Pike;M D Krailo;B E Henderson;J T Casagrande

  • Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

    Paul A. Meyers;Cindy L. Schwartz;Mark D. Krailo;John H. Healey

  • Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate

    Paul A. Meyers;Cindy L. Schwartz;Mark Krailo;Eugenie S. Kleinerman

  • The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer : a prospective comparative trial

    Donald G. Skinner;John R. Daniels;Christy A. Russell;Gary Lieskovsky

  • Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group

    Richard B. Womer;Daniel C. West;Mark D. Krailo;Paul S. Dickman

  • Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.

    A J Provisor;L J Ettinger;J B Nachman;M D Krailo

  • Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

    Neyssa M Marina;Sigbjørn Smeland;Stefan S Bielack;Mark Bernstein

  • Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

    Sigbjørn Smeland;Stefan S. Bielack;Jeremy Whelan;Mark Bernstein

  • Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

    Stefan S. Bielack;Sigbjørn Smeland;Jeremy S. Whelan;Neyssa Marina

  • Do regular ovulatory cycles increase breast cancer risk

    Brian E. Henderson;Ronald K. Ross;Howard L. Judd;Mark D. Krailo

  • BREAST CANCER IN YOUNG WOMEN AND USE OF ORAL CONTRACEPTIVES: POSSIBLE MODIFYING EFFECT OF FORMULATION AND AGE AT USE

    M.C. Pike;M.D. Krailo;B.E. Henderson;A. Duke

  • Randomized Comparison of Cisplatin/Vincristine/Fluorouracil and Cisplatin/Continuous Infusion Doxorubicin for Treatment of Pediatric Hepatoblastoma: A Report From the Children’s Cancer Group and the Pediatric Oncology Group

    Jorge A. Ortega;Edwin C. Douglass;James H. Feusner;Marleta Reynolds

  • The effect of compliance with treatment on survival among patients with hematologic malignancies.

    J L Richardson;D R Shelton;M Krailo;A M Levine

  • Dose-intensified compared with standard chemotherapy for nonmetastatic ewing sarcoma family of tumors: A children's oncology group study

    Linda Granowetter;Richard Womer;Meenakshi Devidas;Mark Krailo

  • Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group

    Stacey L. Berg;Susan M. Blaney;Meenakshi Devidas;Tom A. Lampkin

  • Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration

    Rebecka L Meyers;Rudolf Maibach;Eiso Hiyama;Beate Häberle

  • Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.

    Malcolm A. Smith;Lawrence Rubinstein;James R. Anderson;Diane Arthur

  • Progress in Childhood Cancer: 50 Years of Research Collaboration, A Report from the Children's Oncology Group

    Maura O'Leary;Mark Krailo;James R. Anderson;Gregory H. Reaman

  • Breast Cancer in Young Women and Use of Oral Contraceptives: Possible Modifying Effect of Formulation and Age At Use

    M. C. Pike;B. E. Henderson;M. D. Krailo;A. Duke

Frequent Co-Authors

Richard Gorlick
Richard Gorlick The University of Texas MD Anderson Cancer Center
Peter C. Adamson
Peter C. Adamson Children's Hospital of Philadelphia
Holcombe E. Grier
Holcombe E. Grier Harvard University
Paul A. Meyers
Paul A. Meyers Memorial Sloan Kettering Cancer Center
Susan M. Blaney
Susan M. Blaney Baylor College of Medicine
Mark C. Gebhardt
Mark C. Gebhardt Harvard Medical School
Carlos Rodriguez-Galindo
Carlos Rodriguez-Galindo St. Jude Children's Research Hospital
Frederick J. Rescorla
Frederick J. Rescorla Indiana University
John H. Healey
John H. Healey Memorial Sloan Kettering Cancer Center
Stephen L. Lessnick
Stephen L. Lessnick Nationwide Children's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine goes beyond becoming a doctor. Many students consider related fields that support the healthcare system and offer strong job prospects. Online degrees make it easier than ever to balance studies with your current commitments, whether you are looking to advance your career or switch fields.

For those interested in mental health, online msn pmhnp programs can lead to rewarding roles as psychiatric nurse practitioners. If leadership or management in healthcare appeals to you, an affordable mha online can set you on the pathway to becoming a healthcare administrator.

Concerned about costs? There are options like the cheapest online health science degree, which allows you to start your journey in healthcare without financial strain. For advanced nursing practice, check out the least expensive dnp programs to boost your qualifications for more specialized roles.

These online programs open up flexible career pathways in the fast-evolving world of healthcare—offering more ways to make a difference and shape your future, even outside of traditional medical school paths.

Best Scientists Citing Mark Krailo

Trending Scientists

Recently Published Articles